Immunogenic MUC5AC, a mature MUC5AC detected by Niemann Pick C1 (NPC-1C) and PAM-4 (Clivatuzumab tetraxetan) antibodies failed to improve outcomes in PDA patients. The gene discussed is MUC5AC; the disease is Patent ductus arteriosus.